| abstract |
The invention concerns the use of the APRO4 protein, or an equivalent protein or protein fraction having a proline-rich C-terminal domain, for negatively regulating the Src protein tyrosine kinase activity, and the preparation of pharmaceutical compositions containing such a protein or protein fraction. The invention is particularly useful for preventing and/or treating cancers, in particular colon, pancreatic and breast cancer, osteoporosis and derivative bone diseases, and cerebral and myocardial ischemiae. |